Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QL00 | ISIN: US28617K1016 | Ticker-Symbol: 2TK
Tradegate
25.06.25 | 20:10
2,440 Euro
+6,09 % +0,140
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ELEDON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ELEDON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,2602,34013:03
2,2002,38027.06.

Aktuelle News zur ELEDON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoEledon stock rating reiterated as Overweight by Cantor Fitzgerald1
ELEDON PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City2
18.06.H.C. Wainwright assumes coverage on Eledon stock with buy rating1
12.06.Eledon Pharmaceuticals, Inc. - 8-K, Current Report2
15.05.Cantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stock2
15.05.Eledon Pharmaceuticals GAAP EPS of -$0.081
14.05.Eledon Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
14.05.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results96On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant...
► Artikel lesen
07.04.Eledon Pharmaceuticals, Inc. - 8-K, Current Report1
20.03.Eledon Pharmaceuticals, Inc. - 10-K, Annual Report1
20.03.Eledon Pharmaceuticals GAAP EPS of -$0.75 misses by $0.041
20.03.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results125Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced...
► Artikel lesen
20.03.Eledon Pharmaceuticals, Inc. - 8-K, Current Report1
07.02.Eledon's tegoprubart used in second pig-to-human kidney transplant1
07.02.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human307Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets...
► Artikel lesen
13.01.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook167Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated...
► Artikel lesen
12.11.24Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results405Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive...
► Artikel lesen
29.10.24Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet ...242- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose...
► Artikel lesen
04.09.24Eledon Pharmaceuticals, Inc.: Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients282IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical...
► Artikel lesen
14.08.24Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results273Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment)...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1